June 2024. Volume 20. Number 2

Levetiracetam and lamotrigine in monotherapy produce a lower risk of malformations during pregnancy

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bromley R, Adab N, Bluett-Duncan M, Clayton-Smith J, Christensen J, Edwards K, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2023;8(8):CD010224.

Reviewers: Cabrera Morente L1, Aparicio Rodrigo M2.
1Pediatra. CS San Felipe. Distrito Sanitario de Jaén. Jaén. España.
2Pediatra. CS Entrevías. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
Correspondence: Laura Cabrera Morente. Email: lauramorente@hotmail.com
Reception date: 12/04/2024
Acceptance date: 24/05/2024
Publication date: 05/06/2024

Abstract

Authors´ conclusions: exposure in the womb to certain anti-seizure medications was associated with an increased risk of certain major congenital malformations which, in many cases, is dose dependent. Levetiracetam and lamotrigine appear to be the anti-seizure medications associated with the lowest level of risk, but more data are needed, particularly concerning individual types of malformation and higher doses. For many of the antiseizure medications considered in this review, there were too little data to reach conclusions.

Reviewers´ commentary: this review provides guidance on the most appropriate antiepileptic drug for patients with epilepsy who decide to become pregnant, so that they could try to change to less teratogenic drugs (the most advisable are Lamotrigine or Levetiracetam) prior to pregnancy and try to reduce the dose of dose-dependent antiepileptic drugs (valproate, phenobarbital, carbamazepine or lamotrigine).

How to cite this article

Cabrera Morente l, Aparicio Rodrigo M. Levetiracetam y lamotrigina en monoterapia producen menor riesgo de malformaciones durante el embarazo. Evid Pediatr. 2024;20:24.

AVC | Critically appraised articles

Bromley R, Adab N, Bluett-Duncan M, Clayton-Smith J, Christensen J, Edwards K, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2023;8(8):CD010224.

Reviewers: Cabrera Morente L1, Aparicio Rodrigo M2.
1Pediatra. CS San Felipe. Distrito Sanitario de Jaén. Jaén. España.
2Pediatra. CS Entrevías. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
Correspondence: Laura Cabrera Morente. Email: lauramorente@hotmail.com
Reception date: 12/04/2024
Acceptance date: 24/05/2024
Publication date: 05/06/2024

How to cite this article

Cabrera Morente l, Aparicio Rodrigo M. Levetiracetam y lamotrigina en monoterapia producen menor riesgo de malformaciones durante el embarazo. Evid Pediatr. 2024;20:24.

05/06/2024

Linked Comment